What question did this study set out to answer?

To determine how CYP2C19 and fibrinogen genotypes affect the antiplatelet effect of ticagrelor and aspirin.

March 1, 2026

The Impact of CYP2C19 2, 3, CYP4F2 *3, Fibrinogen β (C-148T) genotype and clinical factors on antiplatelet effect during induction of ticagrelor and aspirin therapy

Key Result

Genetic variants CYP2C19 *2, *3, CYP4F2 *3, and Fibrinogen β (C-148T) influence the antiplatelet effect during ticagrelor and aspirin therapy induction.

Key Points

To determine how CYP2C19 and fibrinogen genotypes affect the antiplatelet effect of ticagrelor and aspirin.
Analysis of patients receiving ticagrelor and aspirin therapy
Genotyping for CYP2C19 *2, *3 and CYP4F2 *3
Assessment of fibrinogen β (C-148T) variants
Statistical analysis of genotypes and clinical outcomes
Certain CYP2C19 genotypes were associated with reduced antiplatelet effect
Fibrinogen β (C-148T) genotype showed significant interaction with antiplatelet response
Clinical factors further influenced the efficacy of ticagrelor and aspirin

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

1538-7836 (Electronic).

Bookmark

Cite This Study

Dambrauskienė et al. (Wed,) reported a other. Genetic variants CYP2C19 *2, *3, CYP4F2 *3, and Fibrinogen β (C-148T) influence the antiplatelet effect during ticagrelor and aspirin therapy induction.

synapsesocial.com/papers/69a3d887ec16d51705d2f6da https://doi.org/https://doi.org/10.1111/jth.13325/epdf

The Impact of CYP2C19 *2, *3, CYP4F2 *3, Fibrinogen β (C-148T) genotype and clinical factors on antiplatelet effect during induction of ticagrelor and aspirin therapy